Albany Molecular Research Downgraded to “Neutral” at Zacks (AMRI)
Albany Molecular Research (NASDAQ:AMRI) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report released on Tuesday. They currently have a $23.70 price target on the stock. Zacks‘s price target would indicate a potential upside of 24.47% from the stock’s previous close.
In other Albany Molecular Research news, major shareholder Stuart M. Cable sold 30,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $18.69, for a total value of $560,700.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Albany Molecular Research (NASDAQ:AMRI) traded up 0.63% on Tuesday, hitting $19.16. 232,448 shares of the company’s stock traded hands. Albany Molecular Research has a 52 week low of $9.71 and a 52 week high of $22.30. The stock’s 50-day moving average is $20.12 and its 200-day moving average is $16.85. The company has a market cap of $594.6 million and a P/E ratio of 38.23.
Albany Molecular Research (NASDAQ:AMRI) last released its earnings data on Tuesday, August 5th. The company reported $0.22 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.20 by $0.02. The company had revenue of $68.20 million for the quarter, compared to the consensus estimate of $65.64 million. On average, analysts predict that Albany Molecular Research will post $0.91 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on AMRI. Analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Separately, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.
Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.